Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
FDA provides very specific guidelines to study iPSC-derived MSCs
Company intends to submit an IND application for its iMSC therapy for patients with ARDS associated with COVID-19
CRANFORD, N.J., June 26, 2020 -- (Healthcare Sales & Marketing Network)... Biopharmaceuticals, FDA Citius Pharmaceuticals, Induced Mesenchymal Stem Cells, ARDS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: COVID-19 | Investigational New Drugs | Marketing | Pharmaceuticals | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study